Doreen Chan
Associate Director, Clinical Research Akero Therapeutics
Seminars
Thursday 17th September 2026
Panel Discussion: Defining The Future Mash Treatment Landscape To Prioritize Differentiated Therapies, Optimize Combination Strategies & Establish Long-Term Standards Of Care
3:30 pm
- Defining future standards of care across fibrosis, metabolic dysfunction and advanced disease populations to prioritize differentiated therapies, improving long-term clinical and commercial positioning
- Evaluating how combination strategies and emerging mechanisms will shape the post-Rezdiffra treatment landscape to optimize development planning, enabling stronger therapeutic differentiation and improved patient outcomes
- Identifying the clinical, regulatory and competitive factors that will determine best-in-class therapies to strengthen late-stage development strategies, improving adoption potential and long-term market success
Thursday 17th September 2026
Demonstrating Fibrosis Regression Through Non-Invasive Assessments in the Ph2b SYMMETRY Trial of Efruxifermin: Advancing Development in Compensated Cirrhosis Due to MASH
11:30 am
- Evaluating changes in multiple non-invasive tests to assess fibrosis regression and disease improvement, enabling more comprehensive treatment monitoring and supporting development in advanced MASH populations
- Leveraging longitudinal non-invasive assessment approaches to characterize therapeutic impact over time, improving understanding of disease modification and strengthening clinical decision-making
- Generating evidence of improvement across measures associated with advanced liver disease to support development strategies, enabling greater confidence in therapeutic benefit and improving future patient outcomes
